Yong Seog Oh
14
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
21.4%
3 terminated/withdrawn out of 14 trials
70.0%
-16.5% vs industry average
21%
3 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Beta-blocker vs. Ic Antiarrhythmic Drug for PVC
Role: lead
Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion
Role: lead
Atrial Fibrillation Prevention in Post Coronary Artery Bypass Graft Surgery With Cryoablation for Ganglionic Plexi
Role: lead
Evaluation for Restoration of Erectile Dysfunction After Cardioversion Treatment Trial
Role: lead
Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation
Role: lead
Impact of Right Ventricular Pacing Determined by Electrocardiography
Role: lead
Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes
Role: lead
Decrease Implantation Site INFECTION (DISINFECTION I): a Randomized Controlled Trial
Role: lead
Decrease Implantation Site INFECTION : a Randomized Controlled Trial
Role: lead
Anticoagulation After RFCA
Role: lead
Perioperative Management of Patients With Pacemakers
Role: lead
Atrioventricular Optimization for Dual Chamber Pacemaker
Role: lead
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
Role: lead
Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation
Role: lead
All 14 trials loaded